U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Ganglioneuroblastoma

MedGen UID:
1726218
•Concept ID:
C5420252
•
Neoplastic Process

Definition

Ganglioneuroblastoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Ganglioneuroblastoma

Professional guidelines

PubMed

Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D
Cancer 2022 Nov 1;128(21):3775-3783. Epub 2022 Sep 13 doi: 10.1002/cncr.34445. PMID: 36101004Free PMC Article
Anatomic patterns of relapse and progression following treatment with (131) I-MIBG in relapsed or refractory neuroblastoma.
Fishel Ben Kenan R, Polishchuk AL, Hawkins RA, Braunstein SE, Matthay KK, DuBois SG, Haas-Kogan DA
Pediatr Blood Cancer 2022 Feb;69(2):e29396. Epub 2021 Oct 18 doi: 10.1002/pbc.29396. PMID: 34662499

Recent clinical studies

Etiology

Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D
Cancer 2022 Nov 1;128(21):3775-3783. Epub 2022 Sep 13 doi: 10.1002/cncr.34445. PMID: 36101004Free PMC Article
Anatomic patterns of relapse and progression following treatment with (131) I-MIBG in relapsed or refractory neuroblastoma.
Fishel Ben Kenan R, Polishchuk AL, Hawkins RA, Braunstein SE, Matthay KK, DuBois SG, Haas-Kogan DA
Pediatr Blood Cancer 2022 Feb;69(2):e29396. Epub 2021 Oct 18 doi: 10.1002/pbc.29396. PMID: 34662499
Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort.
Tas ML, Molenaar JJ, Peek AML, Lequin MH, Verdijk RM, de Krijger RR, Tytgat GAM, van Noesel MM
J Pediatr Hematol Oncol 2022 Jan 1;44(1):e5-e13. doi: 10.1097/MPH.0000000000002067. PMID: 33885033Free PMC Article
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R
Lancet Oncol 2017 Jul;18(7):946-957. Epub 2017 May 23 doi: 10.1016/S1470-2045(17)30355-8. PMID: 28549783Free PMC Article
Refractory diarrhea: A paraneoplastic syndrome of neuroblastoma.
Han W, Wang HM
World J Gastroenterol 2015 Jul 7;21(25):7929-32. doi: 10.3748/wjg.v21.i25.7929. PMID: 26167095Free PMC Article

Diagnosis

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to (131) I-MIBG in patients with relapsed/refractory neuroblastoma.
Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG
Pediatr Blood Cancer 2024 Jan;71(1):e30743. Epub 2023 Oct 26 doi: 10.1002/pbc.30743. PMID: 37885116Free PMC Article
Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort.
Tas ML, Molenaar JJ, Peek AML, Lequin MH, Verdijk RM, de Krijger RR, Tytgat GAM, van Noesel MM
J Pediatr Hematol Oncol 2022 Jan 1;44(1):e5-e13. doi: 10.1097/MPH.0000000000002067. PMID: 33885033Free PMC Article
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R
Lancet Oncol 2017 Jul;18(7):946-957. Epub 2017 May 23 doi: 10.1016/S1470-2045(17)30355-8. PMID: 28549783Free PMC Article
Refractory diarrhea: A paraneoplastic syndrome of neuroblastoma.
Han W, Wang HM
World J Gastroenterol 2015 Jul 7;21(25):7929-32. doi: 10.3748/wjg.v21.i25.7929. PMID: 26167095Free PMC Article
Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK
Med Pediatr Oncol 2001 Jan;36(1):194-6. doi: 10.1002/1096-911X(20010101)36:1<194::AID-MPO1046>3.0.CO;2-B. PMID: 11464881

Therapy

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to (131) I-MIBG in patients with relapsed/refractory neuroblastoma.
Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG
Pediatr Blood Cancer 2024 Jan;71(1):e30743. Epub 2023 Oct 26 doi: 10.1002/pbc.30743. PMID: 37885116Free PMC Article
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D
Cancer 2022 Nov 1;128(21):3775-3783. Epub 2022 Sep 13 doi: 10.1002/cncr.34445. PMID: 36101004Free PMC Article
Anatomic patterns of relapse and progression following treatment with (131) I-MIBG in relapsed or refractory neuroblastoma.
Fishel Ben Kenan R, Polishchuk AL, Hawkins RA, Braunstein SE, Matthay KK, DuBois SG, Haas-Kogan DA
Pediatr Blood Cancer 2022 Feb;69(2):e29396. Epub 2021 Oct 18 doi: 10.1002/pbc.29396. PMID: 34662499
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R
Lancet Oncol 2017 Jul;18(7):946-957. Epub 2017 May 23 doi: 10.1016/S1470-2045(17)30355-8. PMID: 28549783Free PMC Article
Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K, Gerald WL, Kushner BH, Larson SM, Hameed M, Cheung NK
Med Pediatr Oncol 2001 Jan;36(1):194-6. doi: 10.1002/1096-911X(20010101)36:1<194::AID-MPO1046>3.0.CO;2-B. PMID: 11464881

Prognosis

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to (131) I-MIBG in patients with relapsed/refractory neuroblastoma.
Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG
Pediatr Blood Cancer 2024 Jan;71(1):e30743. Epub 2023 Oct 26 doi: 10.1002/pbc.30743. PMID: 37885116Free PMC Article
Evaluation of Ki-67 as prognostic factor for pediatric neuroblastoma and the possibility of molecular-targeted drugs with VEGF and PDGFR.
Watanabe S, Suzuki T, Kondo Y, Naoe A, Uga N, Yasui T, Hara F, Tsuchiya T
Minerva Pediatr (Torino) 2023 Aug;75(4):561-566. Epub 2019 Jan 2 doi: 10.23736/S2724-5276.18.05444-0. PMID: 30605998
Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort.
Tas ML, Molenaar JJ, Peek AML, Lequin MH, Verdijk RM, de Krijger RR, Tytgat GAM, van Noesel MM
J Pediatr Hematol Oncol 2022 Jan 1;44(1):e5-e13. doi: 10.1097/MPH.0000000000002067. PMID: 33885033Free PMC Article
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R
Lancet Oncol 2017 Jul;18(7):946-957. Epub 2017 May 23 doi: 10.1016/S1470-2045(17)30355-8. PMID: 28549783Free PMC Article
Refractory diarrhea: A paraneoplastic syndrome of neuroblastoma.
Han W, Wang HM
World J Gastroenterol 2015 Jul 7;21(25):7929-32. doi: 10.3748/wjg.v21.i25.7929. PMID: 26167095Free PMC Article

Clinical prediction guides

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to (131) I-MIBG in patients with relapsed/refractory neuroblastoma.
Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, Park JR, Maris JM, Vo KT, Matthay KK, DuBois SG
Pediatr Blood Cancer 2024 Jan;71(1):e30743. Epub 2023 Oct 26 doi: 10.1002/pbc.30743. PMID: 37885116Free PMC Article
Evaluation of Ki-67 as prognostic factor for pediatric neuroblastoma and the possibility of molecular-targeted drugs with VEGF and PDGFR.
Watanabe S, Suzuki T, Kondo Y, Naoe A, Uga N, Yasui T, Hara F, Tsuchiya T
Minerva Pediatr (Torino) 2023 Aug;75(4):561-566. Epub 2019 Jan 2 doi: 10.23736/S2724-5276.18.05444-0. PMID: 30605998
Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort.
Tas ML, Molenaar JJ, Peek AML, Lequin MH, Verdijk RM, de Krijger RR, Tytgat GAM, van Noesel MM
J Pediatr Hematol Oncol 2022 Jan 1;44(1):e5-e13. doi: 10.1097/MPH.0000000000002067. PMID: 33885033Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...